Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
Galvus Met 50/850 is indicated for:
-
The treatment of type 2 diabetes mellitus in adults
-
Patients inadequately controlled on metformin alone
-
Patients already being treated with vildagliptin and metformin as separate tablets
Pharmacology:
Galvus Met is a fixed-dose combination of two oral antidiabetic drugs:
-
Vildagliptin: A DPP-4 inhibitor that enhances the levels of incretin hormones, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
-
Metformin: A biguanide that improves insulin sensitivity, reduces hepatic glucose production, and decreases intestinal absorption of glucose.
Together, these agents provide complementary mechanisms to improve glycemic control.
Dosage & Administration:
-
One tablet (50/850 mg) twice daily with meals to reduce gastrointestinal side effects
-
Dosage should be individualized based on patient’s current regimen, effectiveness, and tolerance
-
Not recommended in patients with renal impairment (eGFR <45 mL/min/1.73m²)
Interaction:
-
Alcohol increases risk of lactic acidosis
-
May interact with drugs that impair renal function (e.g., NSAIDs, diuretics, ACE inhibitors)
-
Use with caution alongside other antidiabetic agents to avoid hypoglycemia
-
Contrast agents used in imaging may increase risk of renal impairment
Contraindications:
-
Hypersensitivity to vildagliptin, metformin, or any excipients
-
Renal failure or dysfunction
-
Acute or chronic metabolic acidosis (including diabetic ketoacidosis)
-
Severe hepatic impairment
Side Effects:
-
Common: Nausea, diarrhea, headache, dizziness, upper respiratory tract infection
-
Less common: Hypoglycemia (especially when combined with sulfonylureas), abdominal discomfort
-
Rare: Lactic acidosis, liver enzyme elevation, pancreatitis
Pregnancy & Lactation:
-
Pregnancy: Use only if clearly needed and under medical supervision
-
Lactation: Not recommended due to lack of sufficient data on excretion in breast milk
Precautions & Warnings:
-
Monitor renal and hepatic function periodically
-
Discontinue if metabolic acidosis or unexplained symptoms like muscle pain or fatigue occur
-
Do not use in type 1 diabetes or for diabetic ketoacidosis
-
Regular blood glucose monitoring is essential
Therapeutic Class:
Oral Antidiabetic Agents – DPP-4 Inhibitor + Biguanide Combination
Storage Conditions:
Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of the reach of children.
Change Language